Status: Recruiting
A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants
The primary objective of this trial is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 in participants with gout who are XOI intolerant or have failed uricase treatment.
Participants needed: 90
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Crystalys TherapeuticsUpdated: Jun 10, 2026Locations: 17
Eligibility criteria
Between 18 and 75 years of age (inclusive) at the time of signing informed conse... [+5]
History of or presence of kidney stones within 1 year prior to Screening. [+4]